Cytek Total Assets from 2010 to 2025
| CTKB Stock | USD 4.18 0.02 0.48% |
Total Assets | First Reported 2010-12-31 | Previous Quarter 499.5 M | Current Value 415.7 M | Quarterly Volatility 193.6 M |
Check Cytek Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytek Biosciences' main balance sheet or income statement drivers, such as Tax Provision of 336 K, Net Interest Income of 10.9 M or Interest Income of 10.9 M, as well as many indicators such as Price To Sales Ratio of 4.03, Dividend Yield of 0.0 or PTB Ratio of 2.26. Cytek financial statements analysis is a perfect complement when working with Cytek Biosciences Valuation or Volatility modules.
Cytek | Total Assets |
Latest Cytek Biosciences' Total Assets Growth Pattern
Below is the plot of the Total Assets of Cytek Biosciences over the last few years. Total assets refers to the total amount of Cytek Biosciences assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Cytek Biosciences books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Cytek Biosciences' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cytek Biosciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 499.5 M | 10 Years Trend |
|
Total Assets |
| Timeline |
Cytek Total Assets Regression Statistics
| Arithmetic Mean | 207,276,586 | |
| Geometric Mean | 137,423,012 | |
| Coefficient Of Variation | 93.40 | |
| Mean Deviation | 171,144,483 | |
| Median | 70,361,000 | |
| Standard Deviation | 193,588,983 | |
| Sample Variance | 37476.7T | |
| Range | 449.1M | |
| R-Value | 0.83 | |
| Mean Square Error | 12448.5T | |
| R-Squared | 0.69 | |
| Significance | 0.000068 | |
| Slope | 33,775,731 | |
| Total Sum of Squares | 562150.4T |
Cytek Total Assets History
Other Fundumenentals of Cytek Biosciences
Cytek Biosciences Total Assets component correlations
Click cells to compare fundamentals
About Cytek Biosciences Financial Statements
Cytek Biosciences stakeholders use historical fundamental indicators, such as Cytek Biosciences' Total Assets, to determine how well the company is positioned to perform in the future. Although Cytek Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cytek Biosciences' assets and liabilities are reflected in the revenues and expenses on Cytek Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cytek Biosciences. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Assets | 499.5 M | 415.7 M | |
| Intangibles To Total Assets | 0.07 | 0.08 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out the analysis of Cytek Biosciences Correlation against competitors. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.735 | Earnings Share (0.05) | Revenue Per Share | Quarterly Revenue Growth (0.01) | Return On Assets |
The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.